Safety of probiotics that contain lactobacilli or bifidobacteria

被引：357

作者：

Borriello, SP

Hammes, WP

Holzapfel, W

Marteau, P

Schrezenmeir, J

Vaara, M

Valtonen, V

机构：

[1] Cent Publ Hlth Lab, London NW9 5HT, England

[2] Univ Hohenheim, Inst Nutr, D-7000 Stuttgart, Germany

[3] Univ Hohenheim, Inst Food Technol, D-7000 Stuttgart, Germany

[4] Bundesforsch Anstalt Ernahrung, Inst Hyg & Toxicol, Karlsruhe, Germany

[5] Fed Dairy Res Ctr, Kiel, Germany

[6] Hop Europeen Georges Pompidou, Serv Hepatogastroenterol, Paris, France

[7] Univ Helsinki, Cent Hosp, Div Clin Microbiol, Helsinki, Finland

[8] Univ Helsinki, Cent Hosp, Div Infect Dis, Dept Med, Helsinki, Finland

来源：

CLINICAL INFECTIOUS DISEASES | 2003年 / 36卷 / 06期

关键词：

D O I：

10.1086/368080

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Lactobacilli and bifidobacteria are extremely rare causes of infection in humans, as are probiotics based on these organisms. This lack of pathogenicity extends across all age groups and to immunocompromised individuals. Strains used for new probiotics should be chosen from the commensal flora of humans and should not carry intrinsic resistance to antibiotics that would prevent treatment of a rare probiotic infection. Vigilance regarding the detection of possible rare cases of infection due to probiotics should be maintained, and isolates should be sent to reference centers for molecular characterization and confirmation.

引用

页码：775 / 780

页数：6

共 33 条

[1] Molecular identification and cluster analysis of homofermentative thermophilic lactobacilli isolated from dairy products [J].